肿瘤学中的PET/CT：它是哪些肿瘤的参考标准？
PET/CT in oncology: for which tumours is it the reference standard?
作者信息
Collins Conor D
机构信息
St. Vincent's University Hospital, Dublin, Ireland.
出版信息
Cancer Imaging. 2007 Oct 1;7 Spec No A(Special issue A):S77-87. doi: 10.1102/1470-7330.2007.9008.
Abstract
Positron emission tomography (PET)/computed tomography (CT) has a growing role in the imaging of many cancers. As our experience has grown over the past number of years so has our understanding for which cancers it is particularly useful. The value of PET/CT at each stage of the cancer journey is different for each cancer. This review attempts to tease out the role of PET/CT in the common cancers with particular emphasis on where it is the imaging investigation of choice.
摘要
正电子发射断层扫描（PET）/计算机断层扫描（CT）在许多癌症的成像中发挥着越来越重要的作用。在过去几年里，随着我们经验的积累，我们对它在哪些癌症中特别有用的理解也在加深。对于每种癌症，PET/CT在癌症诊疗过程各阶段的价值有所不同。本综述试图梳理出PET/CT在常见癌症中的作用，特别强调其作为首选成像检查的情况。
相似文献
1
PET/CT in oncology: for which tumours is it the reference standard?
Cancer Imaging. 2007 Oct 1;7 Spec No A(Special issue A):S77-87. doi: 10.1102/1470-7330.2007.9008.
2
PET in oncology: will it replace the other modalities?
Semin Nucl Med. 1997 Apr;27(2):94-106. doi: 10.1016/s0001-2998(97)80042-6.
3
[Positron emission tomography (PET) in clinical oncology. Part II].
Rev Esp Med Nucl. 2002 Apr;21(2):131-47; quiz 149-51. doi: 10.1016/s0212-6982(02)72051-x.
4
Positron emission tomography for benign and malignant disease.
Surg Clin North Am. 2011 Feb;91(1):249-66. doi: 10.1016/j.suc.2010.10.012.
5
Clinical applications of PET in oncology.
Radiology. 2004 May;231(2):305-32. doi: 10.1148/radiol.2312021185. Epub 2004 Mar 24.
6
[Cost-effective PET investigations in oncology].
Magy Onkol. 2002;46(3):203-23. Epub 2002 Oct 6.
7
Clinical role of positron emission tomography in oncology.
Lancet Oncol. 2001 Mar;2(3):157-64. doi: 10.1016/s1470-2045(00)00257-6.
8
[Cost-effective PET scans in oncology].
Orv Hetil. 2002 May 26;143(21 Suppl 3):1255-61.
9
Positron emission tomography scanning is coming to a hospital near you soon!
Clin Med (Lond). 2008 Apr;8(2):134-9. doi: 10.7861/clinmedicine.8-2-134.
10
[Diagnostic value of positron emission tomography (PET) in clinical oncology].
Dtsch Med Wochenschr. 2000 May 5;125(18):565-7. doi: 10.1055/s-2007-1024342.
引用本文的文献
1
Cervical cancer evaluated with integrated F-FDG PET/MR.
Oncol Lett. 2019 Aug;18(2):1815-1823. doi: 10.3892/ol.2019.10514. Epub 2019 Jun 21.
2
The Melanoma MAICare Framework: A Microsimulation Model for the Assessment of Individualized Cancer Care.
Cancer Inform. 2016 Jun 15;15:115-27. doi: 10.4137/CIN.S38122. eCollection 2016.
3
Correlation Between Apparent Diffusion Coefficients and Standardized Uptake Values in Hybrid (18)F-FDG PET/MR: Preliminary Results in Rectal Cancer.
Nucl Med Mol Imaging. 2016 Jun;50(2):150-6. doi: 10.1007/s13139-015-0390-9. Epub 2016 Jan 13.
4
A Comparison Study of Esophageal Findings on (18)F-FDG PET/CT and Esophagogastroduodenoscopy.
Nucl Med Mol Imaging. 2016 Jun;50(2):123-9. doi: 10.1007/s13139-015-0376-7. Epub 2015 Oct 16.
5
Integrated whole body MR/PET: where are we?
Korean J Radiol. 2015 Jan-Feb;16(1):32-49. doi: 10.3348/kjr.2015.16.1.32. Epub 2015 Jan 9.
6
Evaluation of Dixon Sequence on Hybrid PET/MR Compared with Contrast-Enhanced PET/CT for PET-Positive Lesions.
Nucl Med Mol Imaging. 2014 Mar;48(1):26-32. doi: 10.1007/s13139-013-0240-6. Epub 2013 Oct 15.
7
PET/MR: a paradigm shift.
Cancer Imaging. 2013 Feb 27;13(1):36-52. doi: 10.1102/1470-7330.2013.0005.
8
Blind spots at oncological CT: lessons learned from PET/CT.
Cancer Imaging. 2012 Aug 10;12(1):259-68. doi: 10.1102/1470-7330.2012.0030.
9
The role of nuclear medicine in modern therapy of cancer.
Tumour Biol. 2012 Jun;33(3):629-40. doi: 10.1007/s13277-012-0373-8. Epub 2012 Mar 24.
10
Whole-body hybrid PET/MRI: ready for clinical use?
Eur J Nucl Med Mol Imaging. 2011 Jun;38(6):992-5. doi: 10.1007/s00259-011-1790-4.
本文引用的文献
1
ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer.
Eur J Cardiothorac Surg. 2007 Jul;32(1):1-8. doi: 10.1016/j.ejcts.2007.01.075. Epub 2007 Apr 19.
2
The role of FDG PET in the management of lymphoma: practical guidelines.
Nucl Med Commun. 2007 May;28(5):355-7. doi: 10.1097/MNM.0b013e3280895e34.
3
The role of FDG PET in the management of lymphoma: what is the evidence base?
Nucl Med Commun. 2007 May;28(5):335-54. doi: 10.1097/MNM.0b013e3280895e23.
4
Breast MRI and 18F FDG PET/CT in the management of breast cancer.
Ann Nucl Med. 2007 Jan;21(1):33-8. doi: 10.1007/BF03033997.
5
FDG PET in preoperative assessment of colorectal liver metastases combining "evidence-based practice" and "technology assessment" methods to develop departmental imaging protocols: should FDG PET be routinely used in the preoperative assessment of patients with colorectal liver metastases?
Acad Radiol. 2007 Apr;14(4):389-97. doi: 10.1016/j.acra.2007.01.015.
6
Direct comparison of [18F]FDG PET/CT with PET alone and with side-by-side PET and CT in patients with malignant melanoma.
Eur J Nucl Med Mol Imaging. 2007 Sep;34(9):1355-64. doi: 10.1007/s00259-006-0358-1. Epub 2007 Feb 13.
7
Accuracy of PET/CT in characterization of solitary pulmonary lesions.
J Nucl Med. 2007 Feb;48(2):214-20.
8
PET/CT: form and function.
Radiology. 2007 Feb;242(2):360-85. doi: 10.1148/radiol.2422051113.
9
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.
J Clin Oncol. 2007 Feb 10;25(5):571-8. doi: 10.1200/JCO.2006.08.2305. Epub 2007 Jan 22.
10
Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma.
Eur J Cancer. 2007 Feb;43(3):557-64. doi: 10.1016/j.ejca.2006.11.014. Epub 2007 Jan 16.
Zotero 插件